Press Release
GBT Reports Recent Business Progress and First Quarter 2020 Financial Results
Achieved Oxbryta® (voxelotor) net revenues of
Approximately 1,650 new patient prescriptions for Oxbryta during the first quarter
Adapted to virtual operations and engagement intended to ensure ongoing access to Oxbryta during the COVID-19 pandemic
Contributed more than
Conference call today at
“Our first quarter performance exceeded our expectations and demonstrates the quality of execution across our entire organization as well as our employees’ commitment to deliver Oxbryta, a first-in-class therapy that directly inhibits the sickling and destruction of red blood cells. We have received positive feedback from patients and physicians, with increased awareness of Oxbryta and many patients responding well,” said
“With the emergence of the COVID-19 pandemic, we quickly adapted our business activities and launch tactics. We focused on ensuring our field teams were fully equipped to support our key stakeholders in an environment with restrictions on in-person meetings. We are encouraged that many healthcare professionals are embracing telemedicine to provide ongoing care for their patients. Additionally, in this challenging environment, I am proud that we expanded our support for the sickle cell disease community with direct donations to organizations providing immediate relief to patients and families across the country.”
Recent Business Progress
Commercial
- Achieved Oxbryta net sales of
$14.1 million in the first quarter of 2020. - Recorded approximately 1,650 new patient prescriptions of Oxbryta during the first quarter, for a total of approximately 2,000 since launch. The vast majority of new patient prescriptions were enrollments into GBT Source™, the company’s patient support program. The number of new patient prescriptions includes patients whose treatment was reimbursed and patients who received free medicine under GBT’s patient assistance program due to insurance not providing coverage or not having insurance.
- Observed a decline in new patient prescriptions beginning in the second half of March due to the COVID-19 pandemic. GBT believes this decline is temporary and expects new patient prescriptions to return to pre-COVID levels once the pandemic subsides.
- Continued to put Oxbryta reimbursement coverage in place, with payers representing 25% of covered lives. GBT has secured coverage policies with Medicaid fee-for-service plans in 11 of 17 priority states. Most payer meetings to review Oxbryta remain on track for completion during the first half of 2020, and GBT believes it will meet the goal of obtaining broad coverage by the end of the year.
Clinical
- Paused new patient screening and enrollment in company-sponsored clinical trials due to the COVID-19 pandemic, while continuing to support patients already enrolled in studies and conduct study-related administrative activities. GBT anticipates restarting enrollment in these clinical trials at an appropriate time and currently does not expect this pause to impact long-term timelines for its clinical trials, including the completion of the HOPE-KIDS 2 post-approval confirmatory study.
Corporate
- Proactively took action intended to support public health efforts to address the COVID-19 pandemic and to ensure uninterrupted access and support for patients who are prescribed Oxbryta. This included temporarily suspending the company’s field team from all in-person interactions to help slow the spread of the virus, and ensuring that GBT Source remained available and fully functional.
- Contributed more than
$350,000 to support the sickle cell disease (SCD) community during the COVID-19 pandemic through grants from the newly createdGBT Community Fund toU.S. non-profit organizations, a donation to theSickle Cell Disease Association of America and personal contributions from GBT’s board of directors and employees.
Financial Results for the First Quarter 2020
Total product sales, net for the first quarter of 2020 was
Cost of sales for the three months ended
Research and development (R&D) expenses for the three months ended March 31, 2020, were $39.8 million compared with $34.5 million for the same period in 2019. The increase in R&D expenses for this comparative period was primarily attributable to increased costs related to preclinical research and manufacturing activities for inclacumab, increased employee-related costs, including non-cash stock compensation expense, and increased costs for other preclinical research activities related to the collaboration that GBT established with Syros Pharmaceuticals, Inc., in
Sales, general and administrative (SG&A) expenses for the three months ended March 31, 2020, were $47.7 million compared with $18.1 million for the same period in 2019. The increase in SG&A expenses for this comparative period was primarily attributable to increased employee-related costs, including non-cash stock compensation expense, and increased professional and consulting services associated with the build-out of the company’s commercial operations and launch of Oxbryta. Total SG&A non-cash stock compensation expense incurred in the three months ended March 31, 2020, was $11.0 million compared with $5.4 million for the same period in 2019.
Net loss for the three months ended March 31, 2020, was $73.0 million compared with $48.9 million for the same period in 2019. Basic and diluted net loss per share for the three months ended March 31, 2020, was $1.20 compared with $0.87 for the same period in 2019. The company expects its operating costs to increase in subsequent quarters due to costs associated with commercialization activities as well as costs associated with the advancement of its clinical pipeline.
Cash, cash equivalents and marketable securities totaled $615.2 million at March 31, 2020, compared with $695.0 million at December 31, 2019. The decrease of
Conference Call Details
GBT will host a conference call today, Wednesday, May 6, 2020, at 4:30 p.m. ET to provide a general business update and discuss the financial results for the first quarter 2020. To participate in the conference call, please dial 877-407-3982 (domestic) or 201-493-6780 (international). A live audio webcast of the conference call can be accessed on GBT’s website at www.gbt.com under the Investors section. An archived audio webcast will be available for one month following the event.
About Sickle Cell Disease
Sickle cell disease (SCD) affects an estimated 100,000 people in the United States and millions of people throughout the world, particularly among those whose ancestors are from sub-Saharan Africa. It also affects people of Hispanic, South Asian, Southern European and Middle Eastern ancestry.1 SCD is a lifelong inherited blood disorder that impacts hemoglobin, a protein carried by red blood cells that delivers oxygen to tissues and organs throughout the body.2 Due to a genetic mutation, people with SCD form abnormal hemoglobin known as sickle hemoglobin. Through a process called hemoglobin polymerization, red blood cells become sickled – deoxygenated, crescent-shaped and rigid.3-5 The sickling process causes hemolytic anemia (low hemoglobin due to red blood cell destruction) and blockages in capillaries and small blood vessels, which impede the flow of blood and oxygen throughout the body. The diminished oxygen delivery to tissues and organs can lead to life-threatening complications, including stroke and irreversible organ damage.5-7
About Oxbryta® (Voxelotor) Tablets
Oxbryta (voxelotor) is an oral, once-daily therapy for patients with sickle cell disease (SCD). Oxbryta works by increasing hemoglobin’s affinity for oxygen. Since oxygenated sickle hemoglobin does not polymerize, GBT believes Oxbryta blocks polymerization and the resultant sickling and destruction of red blood cells. With the potential to improve hemolytic anemia and oxygen delivery, GBT believes that Oxbryta has the potential to modify the course of SCD. On November 25, 2019, Oxbryta received U.S. Food and Drug Administration (FDA) accelerated approval for the treatment of SCD in adults and children 12 years of age and older.7 As a condition of accelerated approval, GBT will continue to study voxelotor in the HOPE-KIDS 2 Study, a post-approval confirmatory study using transcranial Doppler (TCD) flow velocity to assess the ability of Oxbryta to decrease stroke risk in children 2 to 15 years of age.
In recognition of the critical need for new SCD treatments, the FDA granted Oxbryta Breakthrough Therapy, Fast Track, Orphan Drug and Rare Pediatric Disease designations for the treatment of patients with SCD. The European Medicines Agency (EMA) has included voxelotor in its Priority Medicines (PRIME) program, and the European Commission (EC) has designated voxelotor as an orphan medicinal product for the treatment of patients with SCD.
Important Safety Information
Oxbryta should not be taken if the patient has had an allergic reaction to voxelotor or any of the ingredients in Oxbryta. See the end of the patient leaflet for a list of the ingredients in Oxbryta.
Oxbryta can cause serious side effects, including serious allergic reactions. Patients should tell their healthcare provider or get emergency medical help right away if they get rash, hives, shortness of breath or swelling of the face.
Patients receiving exchange transfusions should talk to their healthcare provider about possible difficulties with the interpretation of certain blood tests when taking Oxbryta.
The most common side effects of Oxbryta include headache, diarrhea, stomach (abdominal) pain, nausea, tiredness, rash and fever. These are not all the possible side effects of Oxbryta. Before taking Oxbryta, patients should tell their healthcare provider about all medical conditions, including if they have liver problems; if they are pregnant or plan to become pregnant as it is not known if Oxbryta can harm an unborn baby; or if they are breastfeeding or plan to breastfeed as it is not known if Oxbryta can pass into breastmilk or if it can harm a baby. Patients should not breastfeed during treatment with Oxbryta and for at least 2 weeks after the last dose.
Patients should tell their healthcare provider about all the medicines they take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Some medicines may affect how Oxbryta works. Oxbryta may also affect how other medicines work.
Patients are advised to call their doctor for medical advice about side effects. Side effects can be reported to FDA at 1-800-FDA-1088. Side effects can also be reported to Global Blood Therapeutics at 1-833-428-4968 (1-833-GBT-4YOU).
Full Prescribing Information for Oxbryta is available at Oxbryta.com.
About
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, an underlying cause of SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including statements containing the words “will,” “anticipates,” “plans,” “believes,” “forecast,” “estimates,” “expects” and “intends,” or similar expressions. These forward-looking statements are based on GBT’s current expectations and actual results could differ materially. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. GBT intends these forward-looking statements, including statements regarding GBT’s priorities, commitment, focus, goals and vision; the safety, efficacy and mechanism of action of Oxbryta and other product characteristics; the delivery, availability, use, and commercial and medical potential of Oxbryta; the commercialization of Oxbryta, including the activities and resources of the commercial field team and healthcare professionals; patient use of Oxbryta and GBT Source, including the recent decline in new patient prescriptions and related expectations; access and support for patients prescribed Oxbryta; payer education, meetings and coverage for Oxbryta; ongoing and planned studies of Oxbryta and related protocols, activities and expectations, including with respect to restarting enrollment and the impact on related timelines; GBT’s financial position, outlook, guidance and expectations; transforming the treatment and care of SCD; and advancing GBT’s pipeline, working on new targets and discovering, developing and delivering treatments, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and GBT makes this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect GBT’s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. GBT can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved, and, furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond GBT’s control including, without limitation, risks and uncertainties relating to the COVID-19 pandemic, including the extent and duration of the impact on GBT’s business, including commercialization activities, regulatory efforts, research and development, corporate development activities, and operating results, which will depend on future developments that are highly uncertain and cannot be accurately predicted, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the
References
- Centers for Disease Control and Prevention website. Sickle Cell Disease (SCD). https://www.cdc.gov/ncbddd/sicklecell/data.html. Accessed June 3, 2019.
- National Heart, Lung, and Blood Institute website. Sickle Cell Disease. https://www.nhlbi.nih.gov/health-topics/sickle-cell-disease. Accessed August 5, 2019.
- Rees DC, et al.
Lancet . 2010;376(9757):2018-2031. - Kato GJ, et al. Nat Rev Dis Primers. 2018;4:18010.
- Kato GJ, et al. J Clin Invest. 2017;127(3):750-760.
- Caboot JB, et al. Paediatr Respir Rev. 2014;15(1):17-23.
- Oxbryta (voxelotor) tablets prescribing information. South
San Francisco, Calif. Global Blood Therapeutics, Inc. ; November 2019.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share amounts)
| Three Months Ended |
||||||||
| 2020 | 2019 | |||||||
| (Unaudited) | (Unaudited) | |||||||
| Product sales, net | $ | 14,118 | $ | — | ||||
| Costs and operating expenses: | ||||||||
| Cost of sales | 135 | — | ||||||
| Research and development | 39,773 | 34,468 | ||||||
| Selling, general and administrative | 47,662 | 18,055 | ||||||
| Total costs and operating expenses | 87,570 | 52,523 | ||||||
| Loss from operations | (73,452 | ) | (52,523 | ) | ||||
| Other income (expense): | ||||||||
| Interest income | 2,856 | 3,831 | ||||||
| Interest expenses | (2,314 | ) | (181 | ) | ||||
| Other expenses, net | (116 | ) | (50 | ) | ||||
| Total other income, net | 426 | 3,600 | ||||||
| Net loss | $ | (73,026 | ) | $ | (48,923 | ) | ||
| Basic and diluted net loss per common share | $ | (1.20 | ) | $ | (0.87 | ) | ||
| Weighted-average number of shares used in computing basic and diluted net loss per common share | 60,787,710 | 56,231,587 | ||||||
Condensed Consolidated Balance Sheets
(In thousands)
| Assets | (Unaudited) | |||||||||
| Current assets: | ||||||||||
| Cash and cash equivalents | $ | 315,525 | $ | 302,237 | ||||||
| Short-term marketable securities | 215,295 | 307,732 | ||||||||
| Other current assets | 33,649 | 18,028 | ||||||||
| Total current assets | 564,469 | 627,997 | ||||||||
| Property and equipment, net | 37,329 | 27,113 | ||||||||
| Long-term marketable securities | 84,378 | 85,030 | ||||||||
| Operating lease right-of-use assets | 52,082 | 52,775 | ||||||||
| Other assets | 2,888 | 3,184 | ||||||||
| Total assets | $ | 741,146 |
$ | 796,099 | ||||||
| Liabilities and Stockholders’ Equity | ||||||||||
| Current liabilities | $ | 62,248 | $ | 71,453 | ||||||
| Long-term debt | 73,688 | 73,559 | ||||||||
| Operating lease liabilities, noncurrent | 81,638 | 72,359 | ||||||||
| Other noncurrent liabilities | — | 34 | ||||||||
| Total liabilities | 217,574 | 217,405 | ||||||||
| Total stockholders’ equity | 523,572 | 578,694 | ||||||||
| Total liabilities and stockholders’ equity | $ | 741,146 | $ | 796,099 | ||||||
Contact Information:
650-410-3258
simmergut@gbt.com
650-741-7730
syao@gbt.com
Source: Global Blood Therapeutics, Inc.